Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2022.Feb.11

Announcement of issue price and banks designated to collect and deposit the proceeds

2022.Feb.09

The Active Cancer Immunotherapy OBI-822, has been granted by ANVISA of Brazil to proceed to Phase III Clinical Trial

2022.Feb.09

Supplementary statements on news article

2022.Feb.08

Announcement of preclinical animal study results of OBI’s COVID-19 vaccine

2022.Jan.28

The Active Cancer Immunotherapy OBI-822, has been granted by URPL of Poland to proceed to Phase III Clinical Trial

2022.Jan.25

Announcement of reference date of 2022 cash capital increase and share subscription

2022.Jan.25

The Active Cancer Immunotherapy OBI-822, has been granted by AEMPS of Spain to proceed to Phase III Clinical Trial

2021.Dec.18

The Active Cancer Immunotherapy OBI-822, has been granted by DIGEMID of Peru to proceed to Phase III clinical trial

2021.Dec.15

OBI has filed the application for a Phase II clinical trial for OBI-833, an active cancer immunotherapy, to TFDA

2021.Dec.08

OBI in-licensed “anti-Trop2 antibody” exclusive rights from Biosion

News

Latest news

Events

Latest events